Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
HK Stock MarketDetailed Quotes
SINCO PHARMA (06833)
- 0.189
- 0.0000.00%
Market Closed Apr 30 09:00 CST
384.22MMarket Cap9.95P/E (TTM)
0.000High0.000Low0Volume0.189Open0.189Prev Close0.00Turnover0.00%Turnover Ratio9.95P/E (Static)2.03BShares0.28052wk High0.50P/B384.22MFloat Cap0.15252wk Low0.00Dividend TTM2.03BShs Float2.304Historical High0.002Dividend LFY0.00%Range %0.130Historical Low--Avg Price4000Lot Size1.06%Div Yield TTM1.06%Div Yield LFY
SINCO PHARMA (06833) Income Statement
All
YOY
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -26.11%2.08B | -21.68%1.2B | 11.07%2.82B | 40.06%1.53B | 11.82%2.54B | -3.52%1.09B | 12.23%2.27B | 33.40%1.13B | -1.26%2.02B | 33.12%847.04M |
| Operating income | -26.11%2.08B | -21.68%1.2B | 11.07%2.82B | 40.06%1.53B | 11.82%2.54B | -3.52%1.09B | 12.23%2.27B | 33.40%1.13B | -1.26%2.02B | 33.12%847.04M |
| Cost of sales | 26.13%-1.86B | 21.31%-1.07B | -13.74%-2.52B | -44.38%-1.35B | -12.78%-2.22B | 0.02%-937.58M | -18.48%-1.97B | -36.00%-937.73M | 6.58%-1.66B | -30.66%-689.52M |
| Operating expenses | 26.13%-1.86B | 21.31%-1.07B | -13.74%-2.52B | -44.38%-1.35B | -12.78%-2.22B | 0.02%-937.58M | -18.48%-1.97B | -36.00%-937.73M | 6.58%-1.66B | -30.66%-689.52M |
| Gross profit | -25.96%222.09M | -24.54%130.7M | -7.22%299.94M | 13.55%173.21M | 5.69%323.28M | -20.63%152.55M | -16.19%305.87M | 22.01%192.2M | 33.28%364.95M | 45.08%157.53M |
| Selling expenses | 9.94%-57.57M | 22.14%-28.39M | 31.79%-63.92M | 22.57%-36.47M | 19.91%-93.71M | 30.50%-47.1M | -11.05%-117.02M | -94.32%-67.77M | -17.30%-105.38M | 43.14%-34.87M |
| Administrative expenses | 34.32%-82.75M | 35.48%-39.48M | -15.74%-125.99M | -26.38%-61.19M | -33.70%-108.86M | -29.71%-48.42M | -23.37%-81.42M | -114.21%-37.33M | -62.76%-66M | 13.50%-17.43M |
| Revaluation surplus | ---- | ---- | -64.07%-4.92M | -32.61%-1.78M | -13.94%-3M | -171.86%-1.34M | ---2.63M | ---494K | ---- | ---- |
| -Changes in the fair value of other assets | ---- | ---- | -64.07%-4.92M | -32.61%-1.78M | -13.94%-3M | -171.86%-1.34M | ---2.63M | ---494K | ---- | ---- |
| Impairment and provision | -280.98%-7.1M | -160.00%-11M | 192.39%3.92M | -459.79%-4.23M | 28.37%-4.25M | 87.12%-756K | -592.29%-5.93M | -15,550.00%-5.87M | -383.44%-856K | -98.32%38K |
| -Other impairment is provision | -280.98%-7.1M | -160.00%-11M | 192.39%3.92M | -459.79%-4.23M | 28.37%-4.25M | 87.12%-756K | -592.29%-5.93M | -15,550.00%-5.87M | -383.44%-856K | -98.32%38K |
| Special items of operating profit | 15.01%7.52M | -45.00%3.18M | 665.03%6.54M | 220.60%5.79M | -95.44%855K | -150.81%-4.8M | 389.30%18.76M | 659.41%9.45M | 278.75%3.83M | -38.39%1.24M |
| Operating profit | -28.87%82.2M | -26.98%55.01M | 1.09%115.56M | 50.28%75.33M | -2.81%114.32M | -44.42%50.13M | -40.16%117.63M | -15.33%90.19M | 35.78%196.55M | 239.41%106.51M |
| Financing cost | -103.91%-33.94M | -151.46%-18.46M | -15.31%-16.64M | 0.29%-7.34M | 21.27%-14.43M | 36.64%-7.36M | 37.14%-18.33M | 21.64%-11.62M | -231.52%-29.16M | -1,120.16%-14.83M |
| Earning before tax | -51.21%48.26M | -46.24%36.56M | -0.96%98.92M | 58.98%67.99M | 0.59%99.88M | -45.56%42.77M | -40.68%99.29M | -14.31%78.57M | 23.12%167.39M | 203.93%91.68M |
| Tax | 76.43%-13.41M | 72.43%-12.17M | 1.14%-56.88M | -90.40%-44.12M | -92.86%-57.53M | -39.22%-23.17M | 7.66%-29.83M | -1.48%-16.65M | -81.30%-32.3M | -817.54%-16.4M |
| After-tax profit from continuing operations | -17.11%34.85M | 2.17%24.39M | -0.72%42.05M | 21.82%23.87M | -39.03%42.35M | -68.36%19.6M | -48.58%69.46M | -17.74%61.92M | 14.34%135.08M | 131.98%75.28M |
| Earning after tax | -17.11%34.85M | 2.17%24.39M | -0.72%42.05M | 21.82%23.87M | -39.03%42.35M | -68.36%19.6M | -48.58%69.46M | -17.74%61.92M | 14.34%135.08M | 131.98%75.28M |
| Profit attributable to shareholders | -17.11%34.85M | 2.17%24.39M | -0.72%42.05M | 21.82%23.87M | -39.03%42.35M | -68.36%19.6M | -48.58%69.46M | -17.74%61.92M | 14.34%135.08M | 131.98%75.28M |
| Basic earnings per share | -15.00%0.017 | 2.56%0.012 | 0.00%0.02 | 20.62%0.0117 | -41.18%0.02 | -68.20%0.0097 | -56.41%0.034 | -31.46%0.0305 | 11.43%0.078 | 134.21%0.0445 |
| Diluted earnings per share | -15.00%0.017 | 2.56%0.012 | 0.00%0.02 | 20.62%0.0117 | -41.18%0.02 | -68.20%0.0097 | -56.41%0.034 | -31.46%0.0305 | 11.43%0.078 | 134.21%0.0445 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | Rongcheng (Hong Kong) Certified Public Accountants Limited | -- | Rongcheng (Hong Kong) Certified Public Accountants Limited | -- | Rongcheng (Hong Kong) Certified Public Accountants Limited | -- | Rongcheng (Hong Kong) Certified Public Accountants Limited | -- | Ernst & Young | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"